This abstract reviews some early findings of a promising new drug of the NRTI class (the same class of drugs as AZT, d4T, and similar compounds). DAPD is active against both HIV-1 and the Hepatitis B virus. No major toxicities were seen in initial studies on mice, rats, or two species of monkey. When DAPD was tested against strains of HIV that are resistant to AZT, 3TC, or the non-nucleoside class (for instance, Sustiva and viramune), the drug continued to show good activity in suppressing HIV-1. This was also true for some viral strains with mutations that usually cause widespread resistance to NRTI's (i.e., the SS or SG insertion). This promising compound is in development by the Triangle Pharmaceutical Company, and human studies have begun in HIV-infected patients.